Updated cost-effectiveness analysis of lung cancer screening for Australia, capturing differences in the health economic impact of NELSON and NLST outcomes.

Silvia Behar HarpazMarianne F WeberStephen WadePreston J NgoPavla VaneckovaPeter E A SarichSonya CressmanMartin C TammemagiKwun FongHenry M MarshallAnnette McWilliamsJohn R ZalcbergMichael CaruanaKaren Canfell

Published in: British journal of cancer (2022)

Lung screening could be cost-effective in Australia, contingent on translating trial-like lung cancer mortality benefits to the clinic.

Keyphrases

healthcare
public health
primary care
clinical trial
study protocol
cardiovascular events
randomized controlled trial
phase iii
health information
risk assessment
adipose tissue
social media
weight loss
life cycle